Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Muro/Adams Tri-Nasal Launch Planned For Fall Allergy Season With 250 Reps

Executive Summary

Muro Pharmaceuticals is increasing production to launch its Tri-Nasal intranasal steroid medication by the start of the fall allergy season.

You may also be interested in...



Crossover Study May Show Dose Response For Inhaled Steroids - FDA Cmte.

A crossover study may be one way to show dose response in bioequivalence studies for inhaled corticosteroids, members of the Orally Inhaled & Nasal Drugs Subcommittee of FDA's Pharmaceutical Sciences Advisory Committee agreed at a recent meeting.

Inhaled Steroid Growth Effect Label Should Reflect Product Data - Schering

Inhaled and intranasal corticosteroid products that have demonstrated no effect on pediatric growth should be exempt from FDA's new class labeling for the asthma and allergy drugs, Schering-Plough maintained.

Inhaled Steroid Growth Effect Should Not Discourage First-Line Use - Cmte.

Suppression of growth velocity in pediatric asthma patients should not discourage the first-line use of inhaled corticosteroids, FDA's Pulmonary & Allergy and Endocrine & Metabolism Drugs Advisory Committees determined July 31 at a joint meeting.

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel